Skip to main content
Log in

Management of impulse control disorders in Parkinson’s disease

Current Treatment Options in Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Goodwin FK:Psychiatric side effects of levodopa in man.JAMA 1971, 218:1915–1920.

    Article  PubMed  CAS  Google Scholar 

  2. Uitti RJ, Tanner CM, Rajput AH, et al.:Hypersexuality with antiparkinsonian therapy.Clin Neuropharmacol 1989, 12:375–383.

    Article  PubMed  CAS  Google Scholar 

  3. Giovannoni G, O’Sullivan JD, Turner K, et al.:Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies.J Neurol Neurosurg Psychiatry 2000, 68:423–428.

    Article  PubMed  CAS  Google Scholar 

  4. Evans AH, Lees AJ:Dopamine dysregulation syndrome in Parkinson’s disease.Curr Opin Neurol 2004, 17:393–398.

    Article  PubMed  Google Scholar 

  5. Of major importance Weintraub D, Siderowf AD, Potenza MN, et al.:Association of dopamine agonist use with impulse control disorders in Parkinson disease.Arch Neurol 2006, 63:969–973. Screening of 272 patients with PD for ICDs, determining prevalence and identifying predictors of developing an ICD.

    Article  PubMed  Google Scholar 

  6. Of major importance Voon V, Hassan K, Zurowski M, et al.:Prevalence of repetitive and reward-seeking behaviors in Parkinson disease.Neurology 2006,67:1254–1257. Case-control study evaluating prevalence of ICDs in patients with PD and associations with dopaminergic medications.

    Article  PubMed  CAS  Google Scholar 

  7. Pontone G, Williams JR, Bassett SS, Marsh L:Clinical features associated with impulse control disorders in Parkinson disease.Neurology 2006, 67:1258–1261.

    Article  PubMed  Google Scholar 

  8. Kurlan R:Disabling repetitive behaviors in Parkinson’s disease.Mov Disord 2004, 19:433–437.

    Article  PubMed  Google Scholar 

  9. Driver-Dunckley E, Samanta J, Stacy M:Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease.Neurology 2003, 61:422–423.

    PubMed  CAS  Google Scholar 

  10. Dodd ML, Klos KJ, Bower JH, et al.:Pathological gambling caused by drugs used to treat Parkinson disease.Arch Neurol 2005, 62:1377–1381.

    Article  PubMed  Google Scholar 

  11. Bearn J, Evans A, Kelleher M, et al.:Recognition of a dopamine replacement therapy dependence syndrome in Parkinson’s disease: a pilot study.Drug Alcohol Depend 2004, 76:305–310.

    Article  PubMed  CAS  Google Scholar 

  12. Pezzella FR, Colosimo C, Vanacore N, et al.:Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease.Mov Disord 2005, 20:77–81.

    Article  PubMed  Google Scholar 

  13. Of major importance Evans AH, Lawrence AD, Potts J, et al.:Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease.Neurology 2005, 65:1570–1574. Identification of factors that predispose to excessive use of dopaminergic therapy.

    Article  PubMed  CAS  Google Scholar 

  14. Imamura A, Uitti RJ, Wszolek ZK:Dopamine agonist therapy for Parkinson disease and pathological gambling.Parkinsonism Relat Disord 2006, 12:506–508.

    Article  PubMed  Google Scholar 

  15. Voon V, Hassan K, Zurowski M, et al.:Prospective prevalence of pathologic gambling and medication association in Parkinson disease.Neurology 2006, 66:1750–1752.

    Article  PubMed  CAS  Google Scholar 

  16. Molina JA, Sainz-Artiga MJ, Faile A, et al.:Pathologic gambling in Parkinson’s disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000, 15:869–872.

    Article  PubMed  CAS  Google Scholar 

  17. Lu C, Bharmal A, Suchowersky O, et al.:Bambling and Parkinson disease.Arch Neurol 2006, 63:298.

    Article  PubMed  Google Scholar 

  18. Aarsland D, Alves G, Larsen JP, et al.: Disorders of motivation, sexual conduct, and sleep in Parkinson’s disease.Adv Neurol 2005, 96:56–64.

    PubMed  Google Scholar 

  19. Of importance Klos KJ, Bower JH, Josephs KA, et al.:Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy.Parkinsonism Relat Disord 2005, 11:381–386. Well-described case series of PD patients with HS and association with the use of DRT.

    Article  PubMed  Google Scholar 

  20. Nirenberg MJ, Waters C:Compulsive eating and weight gain related to dopamine agonist use.Mov Disord 2006, 21:524–529.

    Article  PubMed  Google Scholar 

  21. Friedman JH:Punding on levodopa.Biol Psychiatry 1994, 36:350–351.

    Article  PubMed  CAS  Google Scholar 

  22. Fernandez HH, Friedman JH:Punding on L-dopa.Mov Disord 1999, 14:836–838.

    Article  PubMed  CAS  Google Scholar 

  23. Miwa H, Kondo T:Increased writing activity in Parkinson’s disease: a punding-like behavior? Parkinsonism Relat Disord 2005, 11:323–325.

    Article  PubMed  Google Scholar 

  24. Evans AH, Katzenschlager R, Paviour D, et al.:Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome.Mov Disord 2004, 19: 397–405.

    Article  PubMed  Google Scholar 

  25. Potenza MN, Steinberg MA, Skudlarski P, et al.:Gambling urges in pathological gambling: a functional magnetic resonance imaging study.Arch Gen Psychiatry 2003, 60:828–836.

    Article  PubMed  Google Scholar 

  26. Reuter J, Raedler T, Rose M, et al.: Pathological gambling is linked to reduced activation of the mesolimbic reward system.Nat Neurosci 2005, 8:147–148.

    Article  PubMed  CAS  Google Scholar 

  27. Voon V:Repetition, repetition, and repetition: compulsive and punding behaviors in Parkinson’s disease Mov Disord 2004, 19:367–370.

    Article  PubMed  Google Scholar 

  28. Avanzi M, Uber E, Bonfa F:Pathological gambling in two patients on dopamine replacement therapy for Parkinson’s disease.Neurol Sci 2004, 25:98–101.

    Article  PubMed  CAS  Google Scholar 

  29. Avanzi M, Baratti M, Cabrini S, et al.:Prevalence of pathological gambling in patients with Parkinson’s disease.Mov Disord 2006, 21:2068–2072.

    Article  PubMed  Google Scholar 

  30. Ivanco LS, Bohnen NI:Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study.Am J Ther 2005, 12:467–468.

    Article  PubMed  Google Scholar 

  31. Fernandez HH, Durso R:Clozapine for dopaminergic-induced paraphilias in Parkinson’s disease.Mov Disord 1998, 13:597–598.

    Article  PubMed  CAS  Google Scholar 

  32. Seedat S, Kesler S, Niehaus DJ, Stein DJ:Pathological gambling behaviour: emergence secondary to treatment of Parkinson’s disease with dopaminergic agents.Depress Anxiety 2000, 11:185–186.

    Article  PubMed  CAS  Google Scholar 

  33. Gschwandtner U, Aston J, Renaud S, Fuhr P:Pathologic gambling in patients with Parkinson’s disease.Clin Neuropharmacol 2001, 24:170–172.

    Article  PubMed  CAS  Google Scholar 

  34. Witjas T, Baunez C, Henry JM, et al.:Addiction in Parkinson’s disease: impact of subthalamic nucleus deep brain stimulation.Mov Disord 2005, 20:1052–1055.

    Article  PubMed  Google Scholar 

  35. Bandini F, Primavera A, Pizzorno M, Cocito L:Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson’s disease.Parkinsonism Relat Disord 2006, In press.

  36. Of major importance Ardouin C, Voon V, Worbe Y, et al.:Pathological gambling in Parkinson’s disease improves on chronic subthalamic nucleus stimulation.Mov Disord 2006, 21:1941–1946. Large retrospective chart review identifying patients with preoperative PG who underwent DBS of the STN. Average follow-up of 3.4 years demonstrated improvement in PG in association with decreased dopaminergic medications.

    Article  PubMed  Google Scholar 

  37. Tippmann-Peikert M, Park JG, Boeve BF, et al.:Pathologic gambling in patiens with restless legs syndrome treated with dopaminergic agonists.Neurology 2007, 68:301–303.

    Article  PubMed  CAS  Google Scholar 

  38. Grant JE, Potenza MN:Impulse control disorders: clinical characteristics and pharmacological management.Ann Clin Psychiatry 2004, 16:27–34.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark Stacy MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galpern, W.R., Stacy, M. Management of impulse control disorders in Parkinson’s disease. Curr Treat Options Neurol 9, 189–197 (2007). https://doi.org/10.1007/BF02938408

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02938408

Keywords

Navigation